drugset / Trial / NCT00135525

Study Of Generalized Anxiety Disorder

NCT00135525

Phase 2 Completed GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety in Generalized Anxiety Disorder patients

Timeline

Start
2003-05
Primary completion
2005-10
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg Oral
Subject Paroxetine Small molecule 30 mg Oral
Subject Paroxetine Small molecule 40 mg Oral

Indications